BYT-3156 prodrug

• Treatment for pancreatic cancer and Colon Cancer
• For oral administration, formation of the original parent drug in the human gastrointestinal tract.
• Patents received in the United States, the European Union, Japan and other countries.
• Combination use with other anti-cancer chemotherapy.
• Broad market base with high patient count.

BYT-3156 is a nucleoside-based oral drug, suitable for the treatment of cancer patients, including pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer, and bladder cancer. Combination use with other oral anticancer drugs can reduce side effects, and new indications will also be explored.

BYT-3156 is compound selected/screened from hundreds of internally synthesized prodrugs. Through extensive experiments and texts on efficacy, toxicology, pharmacology, cell biochemistry, etc., BYT-3156 is the right candidate to be developed commercially with huge market potential. BYT-3156 is an inhouse-developed candidate by our expert research team, in collaboration with Academia Sinica, National Taiwan University, College of Medicine of Drug Research Center and Taipei Medical University, BYT-3156 not only twice received SBIR awards from Department of the Ministry of Economic Affairs, but also been selected by the Food and Drug Administration of Ministry of Health and Welfare of Taiwan and qualified as biotechnology new drug.

U.S. patent received on February 17, 2015, certificate number US8,956,613 B2

U.S. patent received on January 10, 2017, certificate number US9,540,410 B2

Taiwan patent received on February 11, 2017, certificate number I569800

Current status

• Pre-clinical preparation